Other examples include recurrent mutations of the chromatin remodeling protein ATRX in lower grade glioblastoma (40% of patient) [20], or DNMT3A and TET2 in acute myeloid leukemia (25% and 8.6% of patients, respectively) [21, 22], mutations of the H3K4 methyltransferase MLL3 in 7.7% of breast cancer patients [23], or mutations of the bromodomain containing protein PBRM1 in 28.5% of kidney renal clear cell carcinoma [24]. This evidence concerns the gene DNMT3A and breast carcinoma.